Table 2.
Thirty-day acute complications results
| All acute complications | ||||
|---|---|---|---|---|
| L-VVI rate (%) | TV-VVI rate (%) | Unadjusted OR (confidence interval) |
Adjusted OR (confidence interval) |
|
| COPD | 9.6 | 8.6 | 1.139 (0.916–1.416) |
1.049 (0.833–1.322) |
| Diabetes | 8.9 | 7.4 | 1.227 (1.012–1.487) |
1.077 (0.879–1.319) |
| ȃDiabetes with high aDCSI | 9.8 | 7.9 | 1.279 (0.987–1.656) |
1.100 (0.837–1.447) |
| ESRD or CKD Stages 4 and 5 | 13.2 | 10.6 | 1.279 (0.938–1.745) |
1.061 (0.755–1.490) |
| ȃESRD | 14.5 | 12.0 | 1.254 (0.820–1.915) |
1.115 (0.716–1.737) |
| ȃCKD Stages 4 and 5 | 12.6 | 10.6 | 1.208 (0.838–1.742) |
1.030 (0.697–1.522) |
| Malignancy | 8.8 | 7.8 | 1.146 (0.905–1.451) |
1.053 (0.827–1.340) |
| ȃMalignancy without treatment | 8.6 | 7.9 | 1.102 (0.852–1.427) |
1.024 (0.785–1.335) |
| ȃTricuspid valve disease | 8.8 | 8.1 | 1.105 (0.878–1.391) |
1.056 (0.832–1.339) |
Odds ratios of 30-day acute complication rates between leadless-VVI patients and transvenous-VVI patients for each high-risk subgroup, estimated with logistic regression models. Confidence Intervals adjusted for multiple comparison (number of tests = 9). ESRD and CKD Stages 4 or 5 are not mutually exclusive.
aDCSI, adapted Diabetes Complication Severity Index; COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease; CKD, chronic kidney disease; L-VVI, leadless-VVI; OR, odds ratios; TV-VVI, transvenous-VVI.